Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer
Gynecologic Oncology Jul 10, 2019
Suzuki K, et al. - The efficacy and toxicity of paclitaxel/carboplatin/bevacizumab were investigated in patients with advanced or recurrent cervical cancer. Thirty-four patients with advanced or recurrent cervical cancer not amenable to curative treatment with surgery or radiation therapy were provided 6 treatment cycles comprising paclitaxel 175 mg/m2, carboplatin area under the curve 6 mg/mL/min, and bevacizumab 15 mg/kg every 21 days until disease progression, complete remission, or limiting toxicity. With an acceptable toxicity level, the combination of paclitaxel/carboplatin/bevacizumab had efficacy with an objective response rate and median overall survival of 88% and 26 months, respectively.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries